丹参川芎嗪注射液联合尿激酶治疗急性心肌梗死的疗效观察

目的探讨丹参川芎嗪注射液联合注射用尿激酶治疗急性心肌梗死的临床疗效。方法选择2016年6月—2017年7月在宣城市中心医院治疗的急性心肌梗死患者65例为研究对象,按照患者所用治疗方案差异将所有患者分为对照组(33例)和治疗组(32例)。对照组给予注射用尿激酶,先静脉推注,50万单位加入到5%葡萄糖溶液20 m L中,而后更改为静脉滴注,50万单位加入到5%葡萄糖液500 m L中,1次/d。治疗组在对照组的基础上静脉滴注丹参川芎嗪注射液,10 m L加入到生理盐水500 m L中,1次/d。两组患者均连续治疗14 d。观察两组的临床疗效,比较两组的心功能指标和血管再通情况。结果治疗后,对照组和治疗组的总有效率分别为75.76%、87.50%,两组比较差异具有统计学意义(P0.05)。治疗后,两组左室射血分数(LVEF)、每搏心输出量(SV)均明显升高,中心静脉压(CVP)明显降低,同组治疗前后比较差异具有统计学意义(P0.05);且治疗组这些观察指标的改善程度明显优于对照组,两组比较差异具有统计学意义(P0.05)。治疗后,对照组和治疗组的血管再通率分别为57.58%、84.38%,两组比较差异具有统计学意义(P0.05)。结论丹参川芎嗪注射液联合注射用尿激酶治疗急性心肌梗死具有较好的临床疗效,可改善心脏功能,提高血管再通率,具有一定的临床推广应用价值。

Clinical observation of Salviae Miltiorrhizae and Ligustrazine Hydrochloride Injection combined with urokinase in treatment of acute myocardial infarction

Objective To investigate the clinical effect of Salviae Miltiorrhizae and Ligustrazine Hydrochloride Injection combined with Urokinase for injection in treatment of acute myocardial infarction. Methods Patients (65 cases) with acute myocardial infarction in Xuancheng City Central Hospital from June 2016 to July 2017 were randomly divided into the control group (33 cases) and the treatment group (32 cases). Patients in the control group were given Urokinase for injection, first intravenous injection, 50 000 units added into 5% glucose solution 20 mL, then change to intravenous drip, 50 000 units added into 5% glucose solution 500 mL, once daily. Patients in the treatment group were iv administered with Salviae Miltiorrhizae and Ligustrazine Hydrochloride Injection on the basis of the control group, 10 mL added into normal saline 500 mL, once daily. Patients in two groups were treated for 14 d. After treatment, the clinical efficacies were evaluated, and cardiac function indexes and vascular recanalization in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 75.76% and 87.50%, respectively, and there was difference between two groups (P < 0.05). After treatment, LVEF and SV in two groups were significantly increased, but CVP in two groups were significantly decreased, and the difference was statistically significant in the same group (P < 0.05). And the observational indexes in the treatment group were significantly better than those in the control group, with significant difference between two groups (P < 0.05). After treatment, the vascular recanalization rates in the control and treatment groups were 57.58% and 84.38%, respectively, and there was difference between two groups (P < 0.05). Conclusion Salviae Miltiorrhizae and Ligustrazine Hydrochloride Injection combined with Urokinase for injection has clinical curative effect in treatment of acute myocardial infarction, can improve cardiac function, and increase vascular recanalization rate, which has a certain clinical application value.